Lonafarnib

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Titrating-Dose of Lonafarnib in Combination With Ritonavir

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Lonafarnib for Chronic Hepatitis D

Lonafarnib in Metastatic Breast Cancer

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

Combination Chemotherapy in Treating Patients With Advanced Cancer